170 related articles for article (PubMed ID: 27518175)
1. Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis.
Yang H; Cui X; Ma Z; Liu L
J Pharm Pharm Sci; 2016; 19(2):274-89. PubMed ID: 27518175
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
Yang H; Zhang C; Zhou Q; Wang Y; Chen L
PLoS One; 2015; 10(1):e0116769. PubMed ID: 25575030
[TBL] [Abstract][Full Text] [Related]
3. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
Mah GT; Mabasa VH; Chow I; Ensom MH
Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Attivi D; Gibaud S
Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
[TBL] [Abstract][Full Text] [Related]
8. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
9. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
Jansen JP; Kumar R; Carmeli Y
Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
[TBL] [Abstract][Full Text] [Related]
12. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
Lee GC; Liou H; Yee R; Quan CF; Neldner K
Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
15. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
16. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.
Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA
Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995
[TBL] [Abstract][Full Text] [Related]
17. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
An MM; Zou Z; Shen H; Zhang JD; Chen ML; Liu P; Wang R; Jiang YY
BMC Infect Dis; 2009 Dec; 9():193. PubMed ID: 19951447
[TBL] [Abstract][Full Text] [Related]
18. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
[TBL] [Abstract][Full Text] [Related]
19. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
